Dr. Reddys USA entered a license agreement with Ingenus Pharmaceuticals, LLC for exclusive rights to commercialize Cyclophosphamide Injection RTD in the U.S. Sales of the product for the past 12 months ended March 2024 were $51.8 million.
AI Assistant
Dr Reddy's Laboratories Ltd
2024
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.